Related Experiment Video

Updated: Aug 31, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Design, Synthesis, and Activity Assays of Cyclin-Dependent Kinase 1 Inhibitors With Flavone Scaffolds

Lanlan Fu1, Jiajia Mou1, Yanru Deng1

  • 1School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, China.

Frontiers in Chemistry
|August 25, 2022
PubMed

Insights

A novel flavone derivative, compound 2a, shows potent Cyclin-dependent kinase 1 (CDK1) inhibition and anti-cancer activity. This compound also demonstrates anti-inflammatory effects, making it a promising lead for drug development.

Area of Science:

  • Medicinal Chemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Cyclin-dependent kinase 1 (CDK1) is crucial for cell cycle regulation and a target for cancer therapy.
  • Flavopiridol, a known pan-CDK inhibitor, provides a basis for designing new CDK1 inhibitors.
  • Previous research established the binding mode of flavopiridol with CDK1.

Purpose of the Study:

  • To discover and evaluate novel flavone derivatives as potential CDK1 inhibitors.
  • To assess the anti-proliferative and anti-inflammatory activities of the synthesized compounds.
  • To investigate the molecular interactions of the most potent compound with CDK1.

Main Methods:

  • Synthesis of a new series of flavone derivatives based on flavopiridol's binding mode.
  • In vitro kinase inhibition assays to determine IC50 values against CDK1.
  • Anti-proliferation assays using cancer cell lines (MCF-7) and immune cells (RAW264.7).
  • Molecular docking simulations to predict binding interactions with CDK1.

Main Results:

  • Compound 2a demonstrated significant CDK1 inhibitory activity (IC50 = 36.42 ± 1.12 μM), comparable to flavopiridol (IC50 = 11.49 ± 0.56 μM).
  • Compound 2a exhibited potent anti-proliferative effects, with greater activity against RAW264.7 cells than MCF-7 cells.
  • Molecular docking revealed that compound 2a forms key hydrogen bonds and hydrophobic interactions within the CDK1 active site.
  • Flavone derivatives showed potential in antagonizing inflammatory responses in addition to inhibiting tumor cell growth.

Conclusions:

  • Compound 2a is a potent CDK1 inhibitor with promising anti-proliferative and anti-inflammatory properties.
  • The findings suggest that flavone derivatives can be developed as dual-acting agents for cancer therapy and inflammation management.
  • Compound 2a serves as a valuable lead compound for the development of novel CDK1 inhibitors.
Keywords:
anti-tumorcyclin-dependent kinase 1derivativeflavoneinhibitor

More Related Videos

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

1.6K
Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

18.8K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
996
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K